Pegloticase: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{CMG}}; {{VB}} {{SB}} ==Overview== Pegloticase (trade name Krystexxa, formerly Puricase)<ref name="www.savientpharma.com">{{Cite web | last = | first = | tit..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}; {{VB}} | {{CMG}}; {{VB}} | ||
{{SB}} | {{SB}} | ||
==Overview== | ==Overview== | ||
| Line 11: | Line 9: | ||
The drug is administered intravenously. | The drug is administered intravenously. | ||
==References== | |||
{{Reflist|2}} | |||
[[Category:Rheumatology]] | |||
[[Category:Immunology]] | |||
{{WH}} | |||
{{WS}} | |||
Revision as of 19:53, 4 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Vidit Bhargava, M.B.B.S [2] Synonyms / Brand Names:
Overview
Pegloticase (trade name Krystexxa, formerly Puricase)[1] is a drug for the treatment of severe, treatment-refractory, chronic gout, developed by Savient Pharmaceuticals.[2] [3] In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue. The European Medicines Agency (EMA) granted marketing authorization in January 2013 for treatment of disabling tophaceous gout. Pegloticase is the first and only drug approved for this indication.
The drug is administered intravenously.
References
- ↑ "http://www.savientpharma.com/pipeline/". Retrieved 4 February 2014. External link in
|title=(help) - ↑ "http://www.ama-assn.org/ama1/pub/upload/mm/365/pegloticase.pdf" (PDF). Retrieved 4 February 2014. External link in
|title=(help) - ↑ "Savient Pharmaceuticals - Savient to Present Multiple Abstracts At the European League Against Rheumatism (EULAR) 2009 Annual Congress". Retrieved 4 February 2014.